Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 5/20 | 0.69 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | XBP1 | P17861 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | STAT1 | P42224 | 1/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2877990 | 0.88 | P2RY1 (0.55) | P2RY1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2880008 | 0.87 | P2RY1 (0.69) | P2RY1MAPTNPSR1KDM4ERAB9A | |
| SCHEMBL2875413 | 0.87 | P2RY1 (0.71) | P2RY1MAPTNPSR1KDM4ERAB9A | |
| SCHEMBL13437657 | 0.86 | P2RY1 (0.71) | P2RY1MAPTNPSR1KDM4ERAB9A | |
| SCHEMBL2872546 | 0.84 | P2RY1 (0.71) | P2RY1MAPTNPSR1KDM4EPKM | |
| SCHEMBL2877891 | 0.82 | P2RY1 (0.77) | P2RY1KDM4EEPHX2P2RY14TRPV1 | |
| SCHEMBL2878288 | 0.81 | P2RY1 (1.00) | P2RY1MAPTNPSR1RAB9ANPC1 | |
| SCHEMBL13063448 | 0.81 | P2RY1 (0.61) | P2RY1MAPTKDM4EPKMRAB9A | |
| SCHEMBL9469328 | 0.80 | P2RY1 (0.57) | P2RY1MAPTNPSR1KDM4ERAB9A | |
| SCHEMBL11726409 | 0.78 | P2RY1 (0.56) | P2RY1MAPTNPSR1KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899299-B1 | C-LINKED CYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-10-20 | — | — | EP | claimed |
| EP-1899299-B1 | C-LINKED CYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-10-20 | — | — | EP | disclosed |
| US-7700620-B2 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700620-B2 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1899299-A2 | C-LINKED CYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | Brystol-Myers Squibb Company (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007002635-A2 | C-LINKED CYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293336-A1 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293336-A1 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | P2RY11, P2RY1, P2RY13 | P2RY1 2/4885MAPT 1893/4885NPSR1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.